20 likes | 50 Views
Oral Mucositis refers to erythematous and ulcerative lesions of the oral mucosa observed in patients with cancer being treated with chemotherapy, and/or with radiation therapy to fields involving the oral cavity.<br><br>In 2017, the total incident cases of Oral Mucositis in the seven major markets was 1,418,879. Similarly, the total treated cases of Oral Mucositis in the 7MM was 1,021,399.<br><br>As per the Delveinsight, the therapeutic market of Oral Mucositis in the 7MM was USD 1,052.7 million in 2017, which is expected to increase during the forecast period. <br><br>Increasing incidence of cancer patients, ongoing research & development and the robust pipeline activity are the key drivers for the Oral Mucositis Market. <br><br>The key players involved in developing therapies for Oral Mucositis includes Innovation Pharmaceuticals, Enzychem Lifesciences Corporation, BrainCool, NeoMedLight, Monopar Therapeutics, MuReva (Lumitex), EpicentRx/Prothex Pharma, Soligenix, Galera Therapeutics and others.<br><br>Source: Oral Mucositis Market<br><br>
E N D